EODData

MEMBERSHIP REGISTER LOG IN

FRA, UJ9: SHANDONG BOAN BIOTECH.H 1

09 Feb 2026
LAST:

0.7650

CHANGE:
 0.03		OPEN:
0.7650		HIGH:
0.7650		ASK:
0.0000		VOLUME:
1.1K
CHG(%):
3.16		PREV:
0.7900		LOW:
0.7650		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
09 Feb 260.76500.76500.76500.76501.1K
06 Feb 260.76500.79000.76500.79001.1K
05 Feb 260.78500.81000.78500.81001.1K
04 Feb 260.77500.80000.77500.80001.1K
03 Feb 260.79000.79000.79000.79000
02 Feb 260.79000.79000.79000.79000
30 Jan 260.82000.82000.81500.81501.1K
29 Jan 260.84000.84000.84000.84001.1K
28 Jan 260.85000.88000.85000.88001.1K
27 Jan 260.87000.87000.87000.87001.1K

PROFILE

Name:SHANDONG BOAN BIOTECH.H 1
About:Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, primary peritoneal cancer, cervical cancer, and hepatocellular carcinoma indications; Boyoubei (BA6101), a human immunoglobulin G2 monoclonal antibody of the RANK ligand for the treatment of postmenopausal women with osteoporosis; and Boluojia (BA1102), a fully human IgG2 anti-RANKL monoclonal antibody to treat bone metastases from solid tumors, and giant cell tumor of bone. It also develops BA5101, a long-acting glucagon-like peptide-1 receptor agonist intended for glycemic control in adults with type 2 diabetes; BA9101, a recombinant human vascular endothelial growth factor receptor antibody fusion protein ophthalmic injection; BA1104, a monoclonal antibody in Phase 3 clinical trial that can enhance the immune response of T cells against tumors by preventing the programmed cell death 1 receptor; BA2101, a long-acting human monoclonal antibody of the IgG4 subtype in Phase 1b/2 trial that targets interleukin-4 receptor subunit a; BA1106, a non-IL-2 blocking anti-CD25 antibody in Phase 1b/2 trial; BA1301, an ADC candidate in Phase 1b/2 trial that targets Claudin 18.2; BA1202, a bi-specific antibody drug in Phase 1a trial that targets CEA/CD3; and BA1302, a CD228-directed ADC in Phase 1a trial. It has an agreement with the Zencore Biologics Co., Ltd. to use its stable cell line development platform non-exclusively, BA-HIEXcell for the development of antibodies and therapeutic proteins. The company was founded in 2013 and is headquartered in Yantai, China. Shandong Boan Biotechnology Co., Ltd. is a subsidiary of Shandong Luye Pharmaceutical Co., Ltd.
Sector:Healthcare
Industry:Biotechnology
Address:No. 39 Keji Avenue, Yantai, China
Website:https://www.boan-bio.com
ISIN:CNE100005RV4

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:89.50 
Price to Sales:0.77 
Price to Book:2.10 
Profit Margin:0.04 
Operating Margin:0.10 
Return on Assets:0.01 
Return on Equity:0.02 
Revenue:91.53M 
EBITDA:21.62M 
Shares:622.33M 
Market Cap:476.09M 

TECHNICAL INDICATORS

MA5:0.793.4%
MA10:0.826.5%
MA20:0.8814.6%
MA50:0.9321.6%
MA100:1.0942.4%
MA200:1.2462.3%
RSI14:32.18 
WPR14:-100.00 
MTM14:-0.12
ROC14:-0.14 
ATR:0.04 
Week High:0.815.9%
Week Low:0.770.0%
Month High:1.0638.6%
Month Low:0.7762.3%
Year High:2.12177.1%
Year Low:0.770.0%
Volatility:97.69